<DOC>
	<DOCNO>NCT00606125</DOCNO>
	<brief_summary>The purpose study : 1 . Evaluate body reacts sorafenib take daily combination paclitaxel carboplatin , 2 . Measure blood level sorafenib , paclitaxel carboplatin specific time take medication , 3 . To determine safety sorafenib .</brief_summary>
	<brief_title>Sorafenib/ Carboplatin/ Paclitaxel Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age &gt; equal 18 year Histological cytological documentation cancer , except non small cell lung cancer ECOG Performance Status 0 1 Life expectancy least 12 week No two prior chemotherapy regimen Adequate bone marrow , liver renal function assess follow : Hemoglobin &gt; equal 9.0 g/dL Absolute neutrophil count ( ANC ) &gt; equal 1,500/mm3 Platelet count &gt; equal 100,000/mm3 Total bilirubin &lt; equal 1.25 time ULN ALT AST &lt; equal 2.5 x ULN PTINR/PTT &lt; 1.5 x ULN ( Patients prophylactically anti coagulate agent coumadin low molecular weight heparin therapeutically anticoagulated LMWH allow participate provide meet criterion ; addition , patient must monitor appropriate interval throughout study ) Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation , include 30 day period last study drug dosing . The investigator advise patient regard adequate mean contraception . Serum creatinine &lt; equal 1.5 x upper limit normal Ability understand willingness sign write informed consent . A sign informed consent must obtain prior study specific procedure Clinically evident congestive heart failure &gt; NYHA Class 2 ( See Appendix 10.4 ) Serious cardiac arrhythmia ( example require antiarrhythmic ) Myocardial infarction symptomatic coronary artery disease ( severe unstable angina ) within 6 month prior screen Active clinically serious infection ( &gt; Grade 2 NCICTC ) Patients history brain metastasis eligible long metastasis treat either stereotactic whole brain radiation , stereotactic gammaknife radiosurgery neurosurgery , patient require ongoing treatment dexamethasone , patient anticoagulant therapy whose radiographic image stable ≥ 4 week start treatment . Time brain metastasis treatment first study treatment must meet following criterion : Stereotactic whole brain radiation , stereotactic gammaknife radiosurgery ≥ 4 week first study treatment Neurosurgery ≥ 24 week first study treatment Brain biopsy ≥ 12 week first study treatment History organ allograft Uncontrolled seizure disorder . Use cytochrome P450 enzymeinducing antiepileptic drug ( phenytoin , carbamazepine phenobarbital ) allow Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management Known human immunodeficiency virus ( HIV ) infection chronic hepatitis B C Peripheral neuropathy &gt; equal Grade 2 Thrombotic embolic event ( transient ischemic attack , myocardial infarction , pulmonary embolus ) , within 6 month prior Screening Pulmonary hemorrhage/bleeding event &gt; CTCAE Grade 2 within 4 week first study treatment Any hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 week first study treatment Evidence history bleed diathesis coagulopathy Serious , nonhealing wound , ulcer , bone fracture Patients undergoing renal dialysis Major surgery , open biopsy significant traumatic injury within 4 week first study treatment Previous cancer EXCEPT cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor [ Ta Tis ] cancer curatively treat &gt; 3 year prior first study treatment Non small cell lung cancer Ongoing substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Pregnant breastfeed patient . Known suspect allergy investigational agent agent give association trial Any condition unstable could jeopardize safety patient compliance study Any condition impair patient 's ability swallow whole pill Any malabsorption condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paclitaxel</keyword>
</DOC>